Background: The roadmap approach is recommended to guide chronic hepatitis B treatment. We evaluated the cost-effectiveness of various treatment strategies in the global market. Methods: Lamivudine and telbivudine were tested in roadmap models with switch-to tenofovir if HBV was detectable at week 24 or add-on tenofovir if resistance developed at year 1. Tenofovir and entecavir were tested as continuous monotherapy. In the reference arm, lamivudine was used with add-on tenofovir if resistance developed at year 1. The primary measure of effectiveness was undetectable HBV DNA at year 2. Cost-effectiveness was measured by incremental cost-effectiveness ratio (ICER) in US dollars against the reference arm. Results: In the US and Germany, costs of the reference arms were US $14,486 and US $9,998 for hepatitis B e antigen (HBeAg)-positive and US $11,398 and US $7,531 for HBeAg-negative patients, respectively. In HBeAgpositive patients, the lamivudine roadmap was most costeffective (ICER US $15,260 in the US and US $29,113 in Germany) with comparable effectiveness (75.1%) to other strategies. In HBeAg-negative patients, tenofovir and entecavir monotherapies were most effective (91-96%) and cost-effective (ICER US $31,297-43,387 in the US and US $53,976-59,822 in Germany). In Asia, where telbivudine cost was lower, both telbivudine and lamivudine roadmaps were cost-effective in HBeAg-positive patients. Tenofovir would be most cost-effective in HBeAg-negative patients if its cost equaled that of telbivudine in Asia. Conclusions: In HBeAg-positive patients, lamivudine roadmap was most cost-effective; in Asia, telbivudine roadmap had comparable cost-effectiveness to lamivudine roadmap because of the relatively low price of telbivudine. In HBeAg-negative patients, entecavir and tenofovir monotherapies were more cost-effective than the roadmap models.
Introduction
HBeAg seroconversion might not be enduring, most authorities recommended that antiviral treatment could be stopped 6-12 months after achieving HBeAg seroconversion and undetectable HBV DNA [1, 2, 11] .
Recent studies demonstrated that low HBV DNA levels after 24 weeks of treatment were associated with favourable 2-year efficacy outcomes in terms of HBeAg seroconversion, undetectable HBV DNA, alanine aminotransferase (ALT) normalization and drug resistance [12] [13] [14] [15] . An expert panel has recommended the roadmap concept, which utilizes the HBV DNA response at week 24 to guide subsequent treatment strategy [16] . Patients with undetectable HBV DNA at week 24 have the lowest risk of developing drug resistance and can continue with the antiviral agent. Patients with detectable HBV DNA at week 24, particularly those who have HBV DNA>10,000 copies/ml, need to add another antiviral agent with no cross-resistance or change to another antiviral agent with higher genetic barrier of resistance. This roadmap approach can potentially identify the suboptimal responders to antiviral agents with low genetic barrier and pre-emptively step up the antiviral treatment to reduce the problem of drug resistance. It is unclear if the roadmap approach is more cost-effective than using drugs with high genetic barrier to resistance as first-line treatment.
Currently, lamivudine, adefovir dipivoxil, entecavir and telbivudine are the oral antiviral agents available worldwide for the treatment of CHB. Tenofovir was recently approved in America and Europe, but it is not yet available in Asia where CHB is most prevalent. Cost-effectiveness of different antiviral treatment strategies would be an important healthcare issue particularly in the planning of public resource allocation. This study was designed to evaluate the cost-effectiveness of roadmap models based on lamivudine and telbivudine as well as tenofovir and entecavir monotherapies in the global market. In addition, because the price of tenofovir in Asian countries has not been set, we also evaluated the cost-effectiveness of tenofovir at different pricing. Many cost-effectiveness studies on CHB treatments utilized Markov models [17] [18] [19] [20] [21] , in which the incremental cost per quality-adjusted life year gained was assessed as the primary outcome; however, Markov models need a lot of hypothetical assumptions because of the lack of clinical data of long-term follow-up. Small changes in each variable would result in a large effect on outcomes in Markov models and sometimes the result can be heavily biased if data from other geographical regions is used; therefore, our study evaluated the cost-effectiveness of roadmap models on the basis of existing clinical data using a shorter term virological outcome (undetectable HBV DNA) at year 2 of treatment. As undetectable HBV DNA is too stringent an outcome measure for pegylated interferon, which has no problems that are associated with drug resistance [22, 23] , we did not compare the cost-effectiveness of pegylated interferon therapy in this analysis.
Methods

Decision model framework
Decision analysis models were constructed to compare five treatment strategies for chronic hepatitis B patients (Figure 1 ). In the first treatment strategy, the reference arm was lamivudine monotherapy with tenofovir salvage, in which patients were given lamivudine 100 mg daily and add-on tenofovir 300 mg daily if viral resistance developed after 12 months of lamivudine use. In the second strategy, tenofovir (300 mg daily) was used as monotherapy for 2 years and no viral resistance was assumed. In the third strategy, entecavir (0.5 mg daily) was used as monotherapy for 2 years and no viral resistance was assumed. In the fourth strategy, in the lamivudine roadmap model, patients were given lamivudine 100 mg daily and switched to tenofovir 300 mg daily if HBV DNA was detectable at week 24; add-on treatment with tenofovir 300 mg daily was commenced if viral resistance developed after 12 months among those remained on lamivudine treatment. In the final strategy, in the telbivudine roadmap model, patients were given telbivudine 600 mg daily and switched to tenofovir 300 mg daily if HBV DNA was detectable at week 24; add-on treatment of tenofovir 300 mg daily was used in case viral resistance developed after 12 months among those remained on telbivudine treatment.
In the lamivudine and telbivudine roadmap models, tenofovir was used for suboptimal responders and drug resistance because of its favourable efficacy over adefovir [11] . The rate of undetectable HBV DNA at year 2 of antiviral therapy was used as the primary outcome measure. Stratified analyses for HBeAg-positive and HBeAg-negative patients were performed. HBeAg seroconversion was also analysed as a secondary outcome measure for HBeAg-positive patients.
Clinical transition probabilities
Clinical transition probabilities were based on the weighted average from several published studies (Table 1, Table 2 and Figure 1 ). The transition probabilities and assumptions made are discussed below.
In the reference arm, the rates of lamivudine resistance at year 1 ranged from 11% to 23% in HBeAg-positive patients [12, [24] [25] [26] and was 12% in HBeAg-negative patients [12, 25] . Patients with lamivudine resistance at year 1 would receive add-on tenofovir. van Bommel et al. [27] reported a 100% rate of undetectable HBV DNA (regardless of the HBeAg status) and a 35% rate of HBeAg loss after switching to tenofovir for 1 year in patients with lamivudine resistance. Here, we assumed the proportions of undetectable HBV DNA at year 2 in both HBeAg-positive and HBeAg-negative patients receiving add-on tenofovir to be 100% and the 2-year HBeAg seroconversion rate to be 35%. Patients without lamivudine resistance at year 1 would continue with lamivudine. The proportions of undetectable HBV DNA at year 2 were 48% for HBeAg-positive patients and 65% for HBeAg-negative patients, respectively [13] , and the 2-year HBeAg seroconversion rates ranged from 28% to 35% [13, 24, 28] .
With 2-year tenofovir monotherapy, the rates of undetectable HBV DNA were 78% for HBeAg-positive patients [29] and 91% for HBeAg-negative patients [30] , and the HBeAg seroconversion rate was 26% [29] .
With 2-year entecavir monotherapy, 73%-80% of HBeAg-positive patients [31, 32] and 96% of HBeAgnegative patients achieved undetectable HBV DNA at year 2 [33] . The 2-year HBeAg seroconversion rates ranged from 19% to 31% [31, 32] .
In the lamivudine roadmap model, 32% of HBeAgpositive patients [12] and 71% of HBeAg-negative patients had undetectable HBV DNA at week 24 [12] . Continuing with lamivudine, 3% of these HBeAgpositive patients [12] and 2% of these HBeAg-negative patients [12] developed lamivudine resistance at year 1; these patients would receive add-on tenofovir, and the proportions of undetectable HBV DNA at year 2 were 100% regardless of the HBeAg status with a 2-year HBeAg seroconversion rate of 35% [27] . For patients without resistance to lamivudine at year 1, lamivudine was continued and the proportions of undetectable HBV DNA at year 2 were 73% for HBeAg-positive patients [34] and 68% for HBeAg-negative patients [13] ; the 2-year HBeAg serovonversion rate was 47% [34] . For patients who did not achieve undetectable HBV DNA with 24-week use of lamivudine, lamivudine would be switched to tenofovir at week 24; the 2-year rates of undetectable HBV DNA in these patients were 76% for the HBeAg-positive group [29] and 73% for the HBeAgnegative group [30] , and the 2-year HBeAg seroconversion rate was 24% [29] . Previous studies demonstrated that among patients who had detectable HBV DNA after 48-week treatment with adefovir, 76% of HBeAgpositive patients and 73% of HBeAg-negative patients would achieve undetectable HBV DNA after switching to tenofovir for a further 48 weeks by intention-to-treat analysis [29, 30] . Here, we assumed the 2-year rates of undetectable HBV DNA in patients treated with 24-week lamivudine with unfavourable early virological response and who switched to tenofovir were 76% in the HBeAg-positive group, and 73% in the HBeAgnegative group, respectively. In the telbivudine roadmap model, 45% of HBeAgpositive patients and 80% of HBeAg-negative patients had undetectable HBV DNA at week 24 [12, 14, 15] . Continuing with telbivudine, 1% of these HBeAgpositive patients and 0% of HBeAg-negative patients developed telbivudine resistance at year 1 [12, 35] ; these patients would receive add-on tenofovir and the proportion of undetectable HBV DNA at year 2 was 100% with a 2-year HBeAg seroconversion rate of 35% [14, 15, 27] . As there was no data regarding the treatment effectiveness of tenofovir on telbivudine-resistant cases, we assumed the treatment responses to be equal to those of lamivudine-resistant cases with tenofovir salvage. For those patients without resistance to telbivudine at year 1, telbivudine was continued and the proportions of undetectable HBV DNA at year 2 were 82% for HBeAg-positive patients and 88% for HBeAgnegative patients [13] [14] [15] ; the 2-year HBeAg seroconversion rate was 46% [13] [14] [15] . For patients who did not achieve undetectable HBV DNA with 24-week use of telbivudine, telbivudine would be switched to tenofovir at week 24; the 2-year rates of undetectable HBV DNA in these patients were 76% for the HBeAgpositive group [29] and 73% for the HBeAg-negative group [30] , and the 2-year HBeAg seroconversion rate was 24% [29] with the same assumptions as described in the lamivudine roadmap model.
Cost estimates
The decision model only included direct treatment costs (the cost of drugs in different countries is listed in in Additional file 1). The costs of blood tests, labour costs for medical consultation, transportation costs to hospital, or productivity lost because of absence of work were not included with the assumption that the expenditures were the same among different treatment strategies. The treatment costs in the US were searched from the internet 36] and local costs were provided by the investigators in Hong Kong, China, Korea, Malaysia, Singapore, Taiwan, Thailand and Germany. The cost of tenofovir was only available in the US and Germany but not in Asia. Unsubsidized cost of the drugs provided by government hospitals were used in the analysis as it could best reflect the resource expenditure in the public health setting. All costs were expressed in US dollars. As the follow-up period was short, no depreciation was considered for the cost estimation.
Cost-effectiveness analyses
Treatment effectiveness was measured in terms of the rates of undetectable HBV DNA and HBeAg seroconversion after 2 years of antiviral therapy. The main outcome of this study was the incremental cost-effectiveness ratio (ICER), that is, the cost difference divided by the effectiveness difference, among treatment strategies against the reference arm. ICER is a measurement used to quantify the cost required to achieve an additional case of undetectable HBV DNA or HBeAg seroconversion at year 2.
Sensitivity analyses
Sensitivity analyses on ICER were conducted to assess the result robustness across different countries. ICERs in the US and Germany were used as references. We calculated ICERs over the possible treatment costs from different Asian countries and the transition probabilities of the model were assumed to be the same. Because tenofovir was not yet available in Asia, we performed further sensitivity analyses with the assumed cost of tenofovir being equal to the local cost of entecavir or telbivudine. All calculations were simulated using Microsoft Excel spreadsheets.
Results
HBeAg-positive chronic hepatitis B
In HBeAg-positive CHB, the cost-effectiveness of different treatment strategies with reference to undetectable HBV DNA at year 2 was shown in Table 3 . The reference arm using lamivudine monotherapy with tenofovir salvage for resistance was the cheapest but least effective in achieving undetectable HBV DNA after 2-year treatment. The cost to achieve a case of undetectable HBV DNA for the reference arm was US $14,486 in the US and US $9,998 in Germany. In the US and Germany, lamivudine was much cheaper than other antiviral agents, whereas the proportions of patients achieving undetectable HBV DNA in 2 years were similar among the two roadmap strategies, entecavir monotherapy and tenofovir monotherapy. Therefore, the lamivudine roadmap model had the lowest ICER, yet with comparable effectiveness, and would be the most cost-effective choice in the US and Germany when undetectable HBV DNA at year 2 was used as the outcome measure. In Asia, tenofovir is not yet available. If the assumed cost of tenofovir was equal to the cost of entecavir, the lamivudine and telbivudine roadmap models, while having high effectiveness in terms of undetectable HBV DNA at year 2, would have comparable ICERs (Table 3) . However, both tenofovir and entecavir monotherapies would have similar effectiveness but much higher ICERs compared with the roadmap models. In this regard, the lamivudine and telbivudine roadmap would be more cost-effective options. By contrast, if the assumed cost of tenofovir in Asia was the same as that of telbivudine, the lamivudine roadmap will have the lowest ICER followed closely by telbivudine roadmap and tenofovir monotherapy.
We also evaluated the treatment effectiveness, in terms of rates of HBeAg seroconversion after 2 years of treatment, and the corresponding ICERs, that is, the additional cost required for one additional case to achieve HBeAg seroconversion in 2 years, of different treatment strategies in different countries. The cost to achieve a case of HBeAg seroconversion for the reference arm was US $29,169 in the US and US $20,130 in Germany. In general, the ICERs for the telbivudine and lamivudine roadmap models to achieve an additional case of HBeAg seroconversion at year 2 were very high, even with the assumption that the cost of tenofovir was set the same as that of telbivudine in Asia (Table 4) .
HBeAg-negative chronic hepatitis B
In HBeAg-negative CHB, the cost to achieve a case of undetectable HBV DNA for the reference arm was US $11,398 in the US and US $7,531 in Germany. Tenofovir and entecavir monotherapies showed higher effectiveness compared with the roadmap models. In the US and Germany, tenofovir monotherapy, with the lowest ICER and high effectiveness, would be the most costeffective option (Table 5) .
In Asia, entecavir and tenofovir monotherapies would be most effective with comparably low ICERs (Table 5) . If the cost of tenofovir was assumed to be the same as that of entecavir in Asia, the telbivudine roadmap model had lower ICER and effectiveness as compared with the entecavir or tenofovir monotherapies. If the assumed cost of tenofovir was the same as that of telbivudine, tenofovir monotherapy would be the unequivocal treatment of choice, with the lowest ICER and very high effectiveness.
Discussion
According to the recommendations by the American Association for the Study of Liver Diseases, entecavir is preferred to lamivudine and telbivudine as a first-line antiviral agent because of its potent viral suppression and favourable resistance profile [1] . Tenofovir is also considered as another first-line antiviral agent in the recent European guideline [11] . Conversely, according to the roadmap concept [16] , antiviral agents with low genetic barriers can still be reasonable treatment options provided that on-treatment response is monitored. In our cost-effectiveness analysis, we found that the lamivudine roadmap, and also the telbivudine roadmap in Asia, were cost-effective in achieving undetectable ICERs of TDF and entecavir (ETV) monotherapies were negative because the 2-year hepatitis B e antigen (HBeAg) seroconversion rate of either therapy was lower than that of the reference arm. HBV DNA at year 2 among HBeAg-positive patients. By contrast, tenofovir and entecavir monotherapies had higher effectiveness and were more cost-effective than the lamivudine or telbivudine roadmap models in achieving undetectable HBV DNA at year 2 among HBeAg-negative patients.
In our analysis, we investigated the cost-effectiveness of the lamivudine and telbivudine roadmap models. According to the latest guidelines of the European Association for the Study of the Liver [11] , in the case of suboptimal early virological response to antiviral agents with low genetic barrier, either a switch to another antiviral agent with higher genetic barrier of resistance or add-on another antiviral agent with no cross-resistance is reasonable treatment of choice. In the lamivudine and telbivudine roadmap models, we therefore used switch-to tenofovir in the case of detectable HBV DNA at week 24, and add-on tenofovir if resistance developed at year 1. However, if add-on tenofovir was employed in both situations, one might anticipate that the costs of the roadmap models would exceed those of tenofovir or entecavir monotherapies in the long run as substantial proportions of patients treated with the roadmap approach would require add-on tenofovir. In other words, if add-on tenofovir was to be used in both circumstances of detectable HBV DNA at week 24 and resistance at year 1, the roadmap models would not be cost-effective regardless of the HBeAg status.
Previous cost-effectiveness studies on CHB treatment have focused on the use of adefovir as a salvage treatment for drug resistance. Several studies have demonstrated that lamivudine with add-on or switch-to adefovir for drug resistance was more cost-effective than lamivudine monotherapy, adefovir monotherapy or no treatment [19] [20] [21] . Veenstra et al. [17] showed that entecavir monotherapy was more cost-effective than lamivudine with adefovir salvage for resistance in HBeAg-positive patients. Spackman and Veenstra [18] demonstrated that in HBeAg-positive patients, initiation with entecavir followed by adefovir salvage was more cost-effective than initiation with adefovir followed by entecavir salvage, or lamivudine or telbivudine followed by adefovir salvage for resistance. As pre-emptive treatment for suboptimal responders can achieve a higher effectiveness in terms of HBV DNA suppression, our study finding that lamivudine and telbivudine roadmap models could serve as cost-effective treatment options in HBeAg-positive patients but not in HBeAg-negative patients would be important for both clinical practice and healthcare resource allocation.
Lamivudine monotherapy with tenofovir salvage for drug resistance was the least effective in HBV DNA suppression. The lamivudine roadmap model had a reasonable effectiveness and, at the same time, was most cost-effective in achieving undetectable HBV DNA at year 2 in HBeAg-positive patients in the US and Germany. As telbivudine was set at a lower price in most countries in Asia, telbivudine the roadmap model had a comparable cost-effectiveness to that of the lamivudine roadmap in HBeAg-positive patients in these areas, even if tenofovir was set at a higher cost similar to that of entecavir. However, if tenofovir was set at a lower price as that of telbivudine, the lamivudine roadmap would become the most cost-effective because of the low cost of pre-emptive treatment for suboptimal responders and salvage treatment for resistance. In other words, the lower cost of telbivudine in Asia, as compared with that in Europe and America, makes the telbivudine roadmap an attractive and costeffective treatment option in the Asian market. The cost-effectiveness of telbivudine treatment could further be improved if patients with favourable baseline Table 5 . Treatment effectiveness, in terms of rates of achieving undetectable HBV DNA after 2-year treatment, and the corresponding ICERs of HBeAg-negative chronic hepatitis B infection in different countries
The order of countries are listed according to the incremental cost-effectiveness ratios (ICERs) of the tenofovir (TDF) monotherapy arm, from the lowest to the highest. Costs of 2-year treatment in the US and Germany (GER) are also listed. [14, 15, 34] . The pricing of tenofovir in Asia would be the crucial determinant of the cost-effectiveness of different treatment strategies; and tenofovir should be set at a competitive price such that patients from financially deprived countries can enjoy its high potency and favourable resistance profile. To extrapolate our findings beyond year 2, we anticipate a small proportion of patients who had undetectable HBV DNA from week 24 until year 2 on lamivudine or telbivudine would develop drug resistance requiring tenofovir salvage, and it would slightly reduce the costeffectiveness of the roadmap models in the long run.
In our study, we demonstrated that very high cost was required to achieve one case of HBeAg seroconversion. The use of more potent antiviral agents could not be translated to a higher rate of HBeAg seroconversion. Telbivudine might be associated with a higher rate of HBeAg seroconversion, based on indirect comparison among trials, and its use under the roadmap model can be considered if a finite course of treatment is considered [11] . For those patients among whom long-term treatment is planned, HBeAg seroconversion is not a useful outcome measure in cost-effectiveness analyses. Similar HBeAg seroconversion rates among different antiviral agents would result in extremely high ICERs.
In HBeAg-negative patients, tenofovir and entecavir monotherapies were more cost-effective than the lamivudine or telbivudine roadmap models in achieving undetectable HBV DNA at year 2 in the US and Germany. The choice of entecavir and tenofovir was further supported by their higher effectiveness as compared with the other treatment strategies. In Asia, the telbivudine roadmap can be a cost-effective strategy depending on the cost of the drugs. If the cost of tenofovir is as high as entecavir, the telbivudine roadmap can be considered as a cost-effective alternative in countries where the expensive drugs are not affordable. However, if the cost of tenofovir could be set as low as that of telbivudine, tenofovir monotherapy would be the most cost-effective treatment option. To extrapolate our findings beyond year 2, a small proportion of good responders to telbivudine and lamivudine in the roadmap models might develop drug resistance and require salvage tenofovir therapy, and it would further increase the cost-effectiveness advantage of tenofovir and entecavir monotherapy.
One common limitation of all cost-effective analyses was that the clinical data was not retrieved from direct comparisons. We attempted to reduce this bias by systemically reviewing the literature and calculating weighted means to account for study sample size. As these studies used different HBV DNA assays with varying sensitivities, the definitions of undetectable HBV DNA were slightly different. This would be slightly disadvantageous to the more recent studies using tenofovir as fewer patients would be able to achieve undetectable HBV DNA under the more sensitive HBV DNA assays [29, 30] . Another limitation was our relatively short-term end points, in which treatment effectiveness was assessed by the 2-year rates of undetectable HBV DNA or HBeAg seroconversion. In this regard, we took advantage of the availability of more complete clinical data while making fewer assumptions as the full cycle Markov model analysis. In the future, our results need to be validated when more long-term results of different antiviral treatment strategies become available. Thirdly, we studied the unsubsidized costs of the drugs for the government hospitals in this cost-effectiveness analysis. The results might be different if subsidized costs were used. In this analysis, on-treatment response monitoring costs were not included. We expected the monitoring of on-treatment response to be similar among patients on different antiviral agents; we therefore only included the drug costs in our analysis and assumed other costs to be the same for various treatment strategies. Lastly, our study did not address all possible antiviral therapy regimes in the current market. We deliberately excluded adefovir in our decision models because of its lower cost and poorer efficacy profiles as compared with tenofovir in western countries. Our study was not designed to investigate the cost-effectiveness of a finite course of pegylated interferon treatment versus a long-term therapy by antiviral agents. manuscript approval. HLYC contributed to the study design, data analysis, manuscript writing, administration and coordination. The study is partially supported by Novartis Pharmaceuticals (HK) Limited.
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